Loyal's Regulatory Moat in Veterinary Care

The real moat here is not just speed to market, it is who has to prove what before selling anything. A supplement company can put soft chews on a website with quality and wellness language, while a drug company has to generate safety, manufacturing, and effectiveness evidence through the FDA animal drug process. That makes Loyal slower and more expensive to build, but it also makes the product legible to vets as medicine rather than as a consumer wellness add on.

• FDA conditional approval for animal drugs still requires a reasonable expectation of effectiveness, plus safety and manufacturing review, and gives up to five years to finish the full effectiveness package. That is very different from supplements, which can sell without an approved drug application.
  1 fda 2 fda 3 fda
• The practical buyer is different. Loyal sells through veterinarians, with daily pills or clinic injections folded into normal chronic care. Leap Years sells daily chews direct to owners and emphasizes cellular health, NAD+, cGMP manufacturing, and NASC registration rather than an FDA drug approval pathway.
  4 sacra 5 leapyears 6 leapyears
• That difference shapes competition. Supplements can test demand fast and cheaply, but if vets, insurers, and large clinic chains become the gatekeepers for longevity treatment, the winner is more likely to be the company with trial data, labeling, and prescription workflows that fit existing animal health channels.
  4 sacra

Going forward, the category is likely to split in two. Supplements will keep building consumer awareness around healthy aging, while the prescription side will define the higher trust, higher price tier. If Loyal converts regulatory progress into routine veterinary prescribing, it can turn longevity from a pet wellness purchase into a standard of care product line.